Adagrasib looks better than Amgen’s Lumakras, which could explain why Mirati has been dragging its heels in lung cancer.
The failed Checkmate-651 study hints at a survival benefit in some PD-L1 expressers, but will this be enough to file?
Glaxo’s anti-PD-1 MAb might not have a market niche to itself for long, while a separate trial could help Keytruda double its adjuvant melanoma potential.
It might be too late for adavosertib, but others could benefit if a niche has finally been found for Wee1 inhibitors.
Clinical data on Carrick’s samuraciclib and Syros’s SY-5609 show that this mechanism remains a work in progress.
Cstone/EQRX and Shanghai Junshi/Coherus might have approvable anti-PD-(L)1 projects, but can Keytruda be challenged on price?
At a conference largely focused on big biopharma a few biotech catalysts stand out.
Full data from the trial position the Pharmamar/Jazz small-cell lung cancer drug to remain safely on the US market.
Full data from the Poseidon study confirm the anti-CTLA-4 MAb’s activity; with three chemo combos established, however, will it be enough?